Delcath Systems, Inc. (DCTH)

Delcath reported Q3 2025 earnings with $20.6 million in revenue and a net income of $0.8 million. The company released its Q4 2025 earnings, reporting revenue of $20.73 million and an EPS of -$0.05, and announced record annual revenue of $85.2 million for 2025. The CHEMOSAT Hepatic Delivery System was included as a recommended liver-directed regional therapy option in the Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline. Delcath reported Q1 2026 results with $25.0 million in revenue but posted a net loss of $1.1 million and reiterated its full-year 2026 revenue guidance of at least $100 million. New data on percutaneous hepatic perfusion with melphalan in liver-dominant metastatic breast cancer was presented at the ESMO Breast Cancer 2026 congress. The CHEMOSAT Hepatic system was recommended for liver treatment, and the results from the Phase 2 CHOPIN trial were published in The Lancet Oncology.

Demand for Delcath Systems, Inc.'s products and services exhibits some seasonality. The company's guidance for 2026 assumes seasonal trends similar to 2025, when new patient start rates declined due to scheduling challenges and an unexpected slowdown in patient engagement during the summer season. Seasonal demand patterns are considered a key risk for the company.

Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers, operating within the Healthcare sector and the Medical Devices industry. The company develops percutaneous perfusion technologies for targeted administration of high-dose chemotherapeutic agents. Its major products include HEPZATO KIT™ in the U.S. and CHEMOSAT® in Europe, designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure. HEPZATO KIT is approved in the U.S. for metastatic uveal melanoma, and CHEMOSAT is approved in Europe for treating a range of liver cancers.

Delcath Systems, Inc. conducts its business operations in the United States and Europe and is headquartered in Queensbury, New York.

Delcath Systems, Inc. has experienced positive developments including a surge in HEPZATO KIT sales, inclusion of CHEMOSAT in clinical practice guidelines, publication of the Phase 2 CHOPIN trial results, record new patient starts, and a consensus "Strong Buy" rating. Events affecting reputation include downward revision of full-year 2025 revenue expectations, a slowdown in patient engagement, softened profitability in Q1 2026, rising operating expenses, slower patient enrollment in the mCRC trial, and modification of the year-end 2026 goal for active treatment centers.

Delcath Systems, Inc. has a mixed ownership structure including institutional shareholders, insider ownership, and retail investors. Institutional shareholders hold percentages ranging from approximately 1.39% to 49.29%. Insider ownership is reported to be around 31.74% to 70.11%. Retail investors hold a significant portion, with one source indicating 50.81%. Major institutional owners include Rosalind Advisors, Inc., BlackRock, Inc., and Vanguard Group Inc. Rosalind Advisors Inc is the largest individual shareholder, holding 9.19 million shares, representing 26.45% of the company. Gil Aharon is another significant insider owner.